Good Manufacturing Practice (GMP): the rules behind every medicine

Good Manufacturing Practice, commonly known as GMP, is the set of rules that medicine manufacturers must follow to ensure their products are consistently safe, effective, and of high quality. GMP is a fundamental requirement for the pharmaceutical industry worldwide. It covers all aspects of production, from the raw materials used to the training of staff and the cleanliness of the facilities. The core principle behind GMP is that quality cannot be tested into a batch of medicine after it is made; instead, quality must be built into the manufacturing process itself. By following these strict guidelines, manufacturers minimise the risks of contamination, mix-ups, and errors that could compromise patient safety.

What GMP Covers

GMP regulations are highly detailed and govern every step of the manufacturing process. A key area of focus is facility design. Factories must be designed to prevent cross-contamination, meaning that the production lines for different medicines must be adequately separated, and the air filtration systems must meet strict standards. The quality of raw materials is also tightly controlled; manufacturers must test the active pharmaceutical ingredients (the chemicals that cause the intended medical effect) and excipients (the inactive ingredients) before using them.

Personnel and documentation are equally important. Staff must be thoroughly trained and wear appropriate protective clothing to maintain a clean environment. Additionally, every step of the process must be meticulously documented. This documentation provides a traceable history of each batch of medicine, allowing regulators to verify exactly how, when, and by whom it was produced. If a problem is detected later, these records are crucial for investigating the root cause.

WHO and PIC/S Standards

While individual countries have their own regulatory bodies, GMP standards are largely harmonised internationally to ensure a consistent level of quality. The World Health Organization (WHO) provides a widely adopted set of GMP guidelines, particularly used by regulatory authorities in developing nations. Another major international framework is the Pharmaceutical Inspection Co-operation Scheme, commonly known as PIC/S. PIC/S is a global cooperative arrangement between regulatory authorities aimed at harmonising inspection procedures so that regulators in different countries can confidently trust each other’s manufacturing oversight.

Many national regulators align their domestic laws with these international standards. In South Africa, the South African Health Products Regulatory Authority (SAHPRA) is responsible for ensuring that all medicines manufactured or imported into the country comply with GMP, often drawing on WHO and PIC/S guidelines. When searching for registered medicines using tools like HealthSA, patients and healthcare providers can rely on the fact that these products have successfully navigated this stringent manufacturing oversight before reaching the market.

Inspections and Licensing

Before a medicine can be legally sold, its manufacturer must obtain a GMP certificate or licence from the relevant regulatory authority. This involves a rigorous inspection of the manufacturing facility. Regulators send inspectors to physically examine the premises, review standard operating procedures, and verify that staff are properly trained. If the facility meets all the required standards, the regulator issues a GMP licence, which is generally valid for a specific period and subject to regular re-inspection.

Inspections are not a one-time event. Regulators conduct routine inspections to ensure ongoing compliance, and they may also perform unannounced inspections if a concern is raised. If a manufacturer wishes to make a change to their production process, such as introducing new equipment or a new active ingredient, they typically must notify the regulator, who may require a new inspection to verify that the changes still meet GMP standards.

Why GMP Failures Trigger Recalls

Despite strict regulations, manufacturing lapses can occur. When a company fails to adhere to GMP, the quality and safety of the medicine are compromised. Common GMP failures include poor sanitation, inadequate testing of raw materials, incomplete documentation, or equipment malfunctions that go unaddressed. Because GMP ensures that the medicine contains the correct ingredients in the right amounts and is free from harmful contaminants, a failure in these processes means the batch cannot be guaranteed safe for public consumption.

When a GMP failure is identified, it often leads to a medicine recall. A recall is the removal of a batch or product from the market because it fails to meet quality standards. Regulators mandate recalls to prevent patients from being exposed to potentially harmful or ineffective medicines. Depending on the severity of the contamination or error, a recall can involve a single batch or an entire product line. In severe cases of GMP violations, regulators may suspend or revoke the manufacturer's licence entirely, halting all production until the issues are fully resolved.